All regulatory updates
718 results found
ASEAN Plan of Action in Combatting Transnational Crime (2026–2035) adopted (enhanced cross-border enforcement cooperation priorities)
ASEAN adopted the ASEAN Plan of Action in Combatting Transnational Crime (2026–2035) at the 19th AMMTC (10 September 2025). Although not a product standard, it is an official ASEAN framework that signals strengthened regional enforcement cooperation and coordination priorities (e.g., on transnational crime themes) and encourages review/harmonisation of relevant national laws and practices. Compliance teams (AML/fraud/cyber/investigations) may use it as an indicator of increased cross-border cooperation and potential alignment of enforcement approaches among ASEAN Member States.
Commission Delegated Directive draft amends Annex III lead exemption 7(a) (high melting temperature solders) by restructuring into sub-entries
A European Commission transparency-register document (dated 8 September 2025) describes a delegated directive intended to amend Directive 2011/65/EU (RoHS) Annex III exemption 7(a) for lead in high-melting-temperature solders. The document indicates the exemption would be restructured into multiple sub-entries (7(a)-I to 7(a)-VII) to better define scope and uses (e.g., different application areas such as interconnections, die attach, sealing and certain lamps/components). Compliance teams relying on exemption 7(a) should monitor the final adopted delegated directive/Official Journal publication and align product documentation to the revised exemption sub-scope once confirmed.
NIOSH updates CBRN Respiratory Protection Handbook (expanded CBRN APR Protection List; fit-testing language correction)
NIOSH published a revised version of the Chemical, Biological, Radiological, and Nuclear (CBRN) Respiratory Protection Handbook (NIOSH Publication 2025-111, revised September 2025). The update expands the CBRN air-purifying respirator (APR) protection list (hazards evaluated/covered) and corrects/clarifies fit-testing language (noting OSHA’s acceptance of qualitative fit testing in certain contexts and correcting prior inclusion/misstatement regarding NFPA fit-testing identification for positive-pressure respirators such as SCBA). This is a compliance-relevant NIOSH guidance update for organizations selecting and managing NIOSH-approved CBRN respirator configurations within respiratory protection programs.
AICIS registration for 2025–26 now open (registration required to introduce industrial chemicals)
AICIS opened the 2025–26 registration period (1 September 2025 to 31 August 2026). The notice reiterates that it is an offence under the Industrial Chemicals Act 2019 to introduce an industrial chemical without an active AICIS registration. Compliance teams should ensure registration is active before any import/manufacture introductions during the registration year and align internal controls to avoid unregistered introductions.
AICIS confirms no changes to AICIS fees and levies for 2025–26 registration year
AICIS published a notice confirming there are no changes to fees and levies for the 2025–26 period; existing registration levies and introduction value thresholds continue unchanged for the registration year starting 1 September 2025. Compliance and finance teams can maintain existing budgeting assumptions for registration and levy planning for the 2025–26 year.
AICIS releases September 2025 Industrial Chemicals Categorisation Guidelines (effective 1 September 2025) including updated high-hazard list
AICIS released the September 2025 Industrial Chemicals Categorisation Guidelines, effective 1 September 2025, including an updated list of chemicals with high hazards for categorisation. AICIS notes additions to the high-hazard list and related clarifications/minor edits. Compliance teams should ensure internal categorisation procedures and screening lists reflect the updated September 2025 guidelines for correct categorisation of introductions.
IDFPR Compliance Capsule reiterates pharmacist cannot refuse to fill a valid controlled-substance prescription solely because it is not electronic (EPCS) and pharmacists are not responsible for enforcing prescriber EPCS compliance
In its Fall 2025 Compliance Capsule newsletter, IDFPR highlights 720 ILCS 570/311.6(e), emphasizing that a pharmacist may not refuse to fill a valid controlled-substance prescription solely because it is not prescribed electronically, and that pharmacists are not responsible for enforcing prescriber compliance with electronic prescribing of controlled substances (EPCS) requirements. This guidance is operationally relevant for pharmacies’ dispensing policies, staff training, and refusal-to-fill procedures, especially where workflows have been configured to reject non-electronic controlled-substance prescriptions.
ASEAN Economic Ministers’ Joint Media Statement sets target to finalize first batch of ATISA Schedules of Non-Conforming Measures by April 2026
The Joint Media Statement of the 57th ASEAN Economic Ministers’ (AEM) Meeting includes a services-integration timeline signal under the ASEAN Trade in Services Agreement (ATISA), noting a target for member states to finalize a first batch of Schedules of Non-Conforming Measures by April 2026. Compliance teams (especially services providers operating cross-border in ASEAN) should monitor progress and published schedules as they can affect market access conditions and sector-specific regulatory constraints under ATISA implementation.
ASME publishes BPV-GUI-01 Guide for ASME Review Teams (General), Issue 2 (dated 2025-08-28), including Section VIII Div. 1-related certification review expectations
ASME issued BPV-GUI-01 (Guide for ASME Review Teams (General)) Issue 2, dated 2025-08-28. The guide/checklist is used in ASME certification review activities and includes items explicitly applicable to Section VIII, Division 1 (e.g., expectations for addressing changes when a demonstration item is built to a prior edition; design control expectations such as computer program verification; and controls for designer qualification/contracted design work). This is guidance affecting certification/quality-system review readiness for VIII-1 certificate holders/applicants rather than a technical Code rule change.
ASME updates BPV-GUI-01 guide for ASME review teams/applicants (Issue 2 dated 2025-08-28) impacting audit expectations for VIII-1 design control
ASME issued BPV-GUI-01 (Guide for ASME Review Teams (General)) Issue 2 (dated 2025-08-28). The guide sets expectations used in joint reviews for ASME Certificates of Authorization (including U/UM), including that the demonstration item should be based on the latest Code Edition in effect at the time of the joint review and that applicants/holders maintain controlled documentation for design calculations/specification control and minimum qualifications/evidence for personnel performing design work (including contracted/outsourced design controls). This guidance is directly relevant to BPVC Section VIII Div.1 compliance management for certificate holders preparing for ASME reviews and maintaining QC program conformance.
ECHA announces target to complete scientific evaluation of proposed EU-wide PFAS restriction by end of 2026
ECHA published a timeline update indicating that its committees aim to complete the scientific evaluation of the proposed EU-wide REACH restriction on PFAS by the end of 2026. This is a procedural milestone (not an adopted restriction) that helps companies forecast when RAC/SEAC opinions may be finalized and when the European Commission could proceed toward a draft restriction decision, enabling earlier planning for potential substitution, essential-use justifications, and stakeholder participation.
ECHA announces target to complete scientific evaluation of proposed REACH PFAS restriction by end of 2026
ECHA published an official timeline update stating it aims to complete the scientific evaluation of the proposed EU-wide PFAS restriction under REACH by the end of 2026. This is a process/timeline signal (not a final restriction), but it is relevant for compliance planning because it frames when committee opinions and subsequent European Commission decision-making could mature. Companies should align internal resourcing (alternatives analyses, socio-economic inputs, supply chain mapping) to the expected 2026 evaluation milestones.
ECHA sets target to complete scientific evaluation of EU-wide PFAS restriction by end of 2026
ECHA published an update on the REACH restriction process for the proposed EU-wide (class-based) PFAS restriction, stating a target to complete the scientific evaluation by the end of 2026. This is a key planning milestone for companies tracking potential future EU restrictions across product categories and industrial uses, informing internal timelines for substitution assessments, supply-chain engagement, and data gathering ahead of committee opinions and subsequent Commission action.
USGS publishes Draft 2025 List of Critical Minerals for public comment (includes multiple rare earth elements)
USGS published a Federal Register notice soliciting public comment on the Draft 2025 List of Critical Minerals. The draft list includes numerous rare earth elements (REEs) and is part of the statutorily required process to update the U.S. critical minerals list. While not a direct product restriction, this list is widely referenced across U.S. government programs (e.g., funding, permitting prioritization, supply-chain policy) and can affect REE-related compliance and procurement expectations in regulated and government-supported projects.
OEHHA Notice of Proposed Rulemaking to amend 27 CCR §25705(b) to add proposed NSRLs for 1-bromopropane and diethanolamine (dermal)
OEHHA issued a Notice of Proposed Rulemaking to amend Title 27 of the California Code of Regulations, section 25705(b), to add new No Significant Risk Levels (NSRLs) used as Proposition 65 cancer “safe harbor” exposure levels. The proposal would add an NSRL of 54 µg/day for 1-bromopropane and an NSRL of 6.4 µg/day for diethanolamine for dermal exposure only (explicitly not applicable to other exposure routes). OEHHA’s notice sets a public comment deadline of October 6, 2025, and provides that a public hearing will be held only if requested by September 22, 2025. Compliance teams may wish to submit comments and, if adopted, consider how these NSRLs affect internal Prop 65 exposure assessments and warning determinations.
ECHA publishes updated PFAS restriction proposal dossier for EU-wide REACH restriction evaluation
ECHA announced publication of an updated background document/dossier for the proposed EU-wide REACH restriction on PFAS, incorporating updates following evaluation of comments from the 2023 consultation. This is not a final restriction, but it updates the technical basis being assessed by RAC/SEAC and can affect anticipated scope, derogations, and evidence used in compliance planning and substitution roadmaps.
ECHA publishes updated PFAS restriction proposal dossier to support ongoing committee evaluation
ECHA announced publication of an updated REACH restriction proposal dossier for PFAS (updated background/proposal materials) as part of the ongoing evaluation of the proposed EU-wide restriction. For compliance teams, the updated dossier can change understanding of scope, derogations, and sector-specific considerations used in RAC/SEAC assessment and provides updated reference material to support company impact assessments and consultation preparation.
ECHA publishes updated REACH PFAS restriction proposal background document following 2023 consultation feedback
ECHA announced publication of an updated PFAS restriction proposal package under REACH, reflecting evaluation of 5,600+ comments received during the 2023 consultation and updates to the background document used by RAC/SEAC in forming opinions. Compliance teams should review whether updated sector descriptions, derogation concepts, and alternatives/conditions discussed in the revised background documentation change internal impact assessments, data-gathering needs, and positions for upcoming committee opinion/consultation stages.
Illinois Public Act 104-0424 extends veterinarians’ exemption from mandatory electronic prescribing requirement
Public Act 104-0424 amends the Illinois Controlled Substances Act electronic prescribing provisions to extend the period during which prescriptions issued by a licensed veterinarian are not required to be issued electronically. The exemption window is extended to 7 years after November 17, 2023 (extended from a prior 2-year window). Compliance teams supporting veterinary prescribing workflows and e-prescribing controls should update policy logic and exception handling based on the amended exemption period.
Illinois enacts Public Act 104-0424 (SB2469) extending veterinarian e-prescribing exception for controlled substances
Illinois enacted Public Act 104-0424 (SB2469), amending 720 ILCS 570/311.6 (electronic prescribing for Schedule II–V controlled substances). The amendment extends the veterinarian exception to the electronic-prescribing requirement: prescriptions issued by a licensed veterinarian are not required to be electronic within 7 years after November 17, 2023 (previously 2 years). Compliance teams supporting veterinary practices and pharmacies should update EPCS compliance logic, workflows, and policy documentation to reflect the extended transition period for veterinarians under Illinois law.